8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): January 16, 2006



                               THERMOGENESIS CORP.
             (Exact name of registrant as specified in its charter)




           Delaware                       0-16375               94-3018487
          ---------                       --------               ----------
(State or other jurisdiction of    (Commission File Number)   (I.R.S. Employer
incorporation or organization)                               Identification No.)


                                2711 Citrus Road
                        Rancho Cordova, California 95742
                        --------------------------------
              (Address and telephone number of principal executive
                               offices) (Zip Code)


                                 (916) 858-5100
                                 --------------
              (Registrant's telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)
[ ]  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)
[ ]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))
[ ]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))






Section 8 - Other Events
- ------------------------

Item 8.01 Other Events.

     On January 3, 2006,  ThermoGenesis Corp. (the "Company") announced that the
Center for Biologics  Evaluation and Research ("CBER") notified the Company that
it was reviewing the Company's  pre-market  application ("PMA") for its CryoSeal
FS System ("CryoSeal").  The PMA submission was based on clinical results from a
Phase III trial  evaluating the safety and efficacy of CryoSeal as an adjunct to
hemostasis in liver resection surgery against the control, INSTAT(R), a collagen
absorbable hemostat.  If approved,  CryoSeal would be the only fibrin sealant on
the market that is produced from the patient's own blood,  and an alternative to
conventional fibrin sealants that are derived from bovine tissue or pooled human
blood.

     Although  CBER  acknowledged  that it was  reviewing  the Company's PMA for
CryoSeal,  no assurance can be given that CBER will not require  further testing
and clinical data, or that CryoSeal will ultimately be approved by the FDA to be
marketed  in the United  States.  If further  testing and  clinical  studies are
required,   there  can  be  no  assurance  that  the  clinical  studies  can  be
successfully  completed within the Company's  expected time frame and budget, or
that such studies will provide required findings for approval. If the Company is
unable to receive FDA approval for CryoSeal,  the Company's business,  financial
condition and results of operations could be adversely affected.

     Additional  information  can be  found on the  press  release  attached  as
Exhibit 99.


Section 9 - Financial Statements and Exhibits
- ---------------------------------------------

Item 9.01 Financial Statements and Exhibits.

   Exhibit No.      Exhibit Description
   -----------      -------------------

      99            Press Release  dated  January 3, 2006 titled  "Thermogenesis
                    Corp. Files PMA to Market CryoSeal(R) Fibrin Sealant (FS) in
                    Liver Resection Surgeries"






                                    SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                        THERMOGENESIS CORP.,
                                        a Delaware Corporation


Dated:  January 16, 2006                /s/ Matthew Plavan
                                        ------------------------------------
                                        Matthew Plavan,
                                        Chief Financial Officer





                                  EXHIBIT INDEX


      Exhibit No.                       Description
      -----------                       -----------

          99        Press Release  dated  January 3, 2006 titled  "Thermogenesis
                    Corp. Files PMA to Market CryoSeal(R) Fibrin Sealant (FS) in
                    Liver Resection Surgeries"

EX-99

                                                                      EXHIBIT 99


                               THERMOGENESIS LOGO


                     THERMOGENESIS CORP. FILES PMA TO MARKET
                       CRYOSEAL(R) FIBRIN SEALANT (FS) IN
                            LIVER RESECTION SURGERIES

            - CryoSeal would be the First Autologous Fibrin Sealant -
                  - Potential FDA Approval Expected Late 2006 -

RANCHO CORDOVA, California (January 3, 2006) - ThermoGenesis Corp (NASDAQ: KOOL)
announced  today that the Center for Biologics  Evaluation  and Research  (CBER)
notified the Company that it was reviewing the Company's pre-market  application
(PMA) for CryoSeal FS. The PMA submission  was based on clinical  results from a
Phase III trial  evaluating the safety and efficacy of CryoSeal FS as an adjunct
to hemostasis in liver resection  surgery against a control,  Instat, a collagen
absorbable hemostat.  The multi-center  randomized and blinded clinical trial of
150 cancer  patients  showed that CryoSeal FS  demonstrated  superiority  to the
Instat control by causing  statistically  significant quicker time to hemostasis
(cessation of bleeding) versus the control group (p-value= <0.001). If approved,
CryoSeal would be the only fibrin sealant  produced from the patient's own blood
(autologous)  on the market and an alternative to  conventional  fibrin sealants
derived from bovine tissue and pooled human bloods which are currently used in a
wide range of surgeries.

Kevin Simpson,  President and COO commented, "This first PMA filing is a pivotal
milestone  signaling our transition from an R&D and clinical stage company to an
operation with recurring disposable revenues. Following regulatory approval, the
CryoSeal FS System  would  provide  the first  `all-autologous'  fibrin  sealant
product to be  marketed in the United  States and Japan  where our  distribution
partner,  Asahi Kasei Medical,  filed documentation  earlier this year to enable
marketing approval."

Japan, at $145 million/year,  and the United States, at $116  million/year,  are
the two largest fibrin sealant markets in a worldwide  market  estimated at over
$450 million/year.

Regulatory Status
- -----------------
ThermoGenesis  Corp.  has been  granted  the  right to affix  the CE Mark to the
CryoSeal FS System by our European Notified Body. The product is being tested in
clinical  trials in Europe.  Additional  field trials are underway in Canada and
Brazil.  In Japan, the pivotal clinical trial was completed in late 2004 and the
PMA was  assembled  in March  2005.  Sales in the United  States will follow FDA
approval of the CryoSeal FS PMA which is expected in late CY 2006.

About ThermoGenesis Corp.
- -------------------------
ThermoGenesis Corp. is a leader in enabling  technologies for cell therapeutics.
The Company's  technology  platforms  lead the world in their ability to produce
biological products from single units of blood.
     o    The  BioArchive(R)  System,  now  distributed by GE Healthcare,  is an
          automated  robotic  cryogenic device, is used by major cord blood stem
          cell  banks  in  26  countries  as  a  key  enabling   technology  for
          cryopreserving and archiving stem cell units for transplant.



     o    The AutoXpress(TM)  System,  currently  undergoing Alpha testing, is a
          semi-automated  robotic  device and  companion  sterile  closed  blood
          processing  disposable,  to harvest stem cells from cord blood. Market
          launch by GE Healthcare is expected in 1Q CY2006.
     o    The CryoSeal FS System, a semi-automated  device and companion sterile
          blood  processing  disposable,  is  used  to  prepare  hemostatic  and
          adhesive  surgical sealants from the patient's blood in about an hour.
          Enrollment in a 150 patient United States and 72 patient Japan pivotal
          clinical  trials have been  completed and the PMAs are under review by
          the United States FDA and the Japanese MHLW.
     o    The Thrombin Processing Device (TPD(TM)) is a sterile blood processing
          disposable  that prepares  activated  thrombin from a small aliquot of
          patient blood, or blood plasma in 25 minutes. The TPD market launch by
          Medtronic and Biomet is underway in Europe.

The  statements  contained in this release  which are not  historical  facts are
forward-looking  statements  that are  subject to risks and  uncertainties  that
could cause  actual  results to differ  materially  from those  expressed in the
forward-looking statements, including, but not limited to, certain delays beyond
the Company's  control with respect to market acceptance of new technologies and
products, delays in testing and evaluation of products, and other risks detailed
from time to time in the  Company's  filings  with the  Securities  and Exchange
Commission.

                         For More Information, Contact:

                               ThermoGenesis Corp.
                        Philip H. Coelho: (916) 858-5100
                          Or Fern Lazar (212) 867-1762
                 or visit the web site at www.thermogenesis.com